Adtec Healthcare Secures $12M to Accelerate Global Rollout of Cold Plasma Wound-Care Technology

London-based medtech firm Adtec Healthcare has secured a $12 million (£9.4 million) investment from two strategic backers — AIPO Fund and SG Biomedical — in a funding round aimed at global expansion and accelerated product development. The company, which spun out from Japan’s industrial plasma specialist Adtec Plasma Technology Co., Ltd. in June 2023, is now poised to scale its cold plasma-based medical device into new markets, particularly the United States.

Adtec Healthcare’s core innovation is its cold atmospheric plasma device, branded as SteriPlas, already CE-marked and in use across European hospitals for chronic wound care, infection control, and antimicrobial-resistant biofilm treatment. With more than 20 years of technology evolution behind it, the company is transitioning from early deployments to full-scale commercial growth.

The new capital will be directed toward several priorities: advancing a next-generation cold plasma medical device, securing FDA regulatory approval for U.S. market entry, ramping up manufacturing capacity, and forging strategic partnerships in global healthcare markets. The funding represents a major milestone in Adtec Healthcare’s shift from R&D to large-scale production and international rollout.

According to the company, this investment demonstrates strong investor confidence in non-antibiotic, non-invasive wound-care therapies—a field gaining urgency amid the global rise of antimicrobial resistance. The leadership team described the funding as validation of its mission to make cold plasma a mainstream clinical therapy for wound healing and infection management.

The 2023 spin-out from Japan’s Adtec Plasma Technology established a dedicated UK-based medtech platform focused on healthcare applications of plasma science. By setting up in the UK, the company gained proximity to European regulatory pathways, hospital networks, and a growing community of wound-care specialists. Now, with the support of AIPO Fund and SG Biomedical, Adtec Healthcare is entering its next growth phase with both financial backing and strategic industry alignment.

AIPO Fund, an investment vehicle targeting deep tech and life sciences, led the round and will support Adtec Healthcare’s scale-up and commercial strategy. SG Biomedical, a specialist investor in medtech and plasma-based healthcare technologies, is expected to provide scientific and regulatory expertise alongside its financial support. Together, the two investors bring a mix of capital and sector experience designed to accelerate Adtec Healthcare’s journey toward FDA clearance and global expansion.

With this funding, Adtec Healthcare plans to expand its engineering and regulatory teams, complete advanced clinical studies, and boost manufacturing capacity for its SteriPlas device. The company also intends to deepen collaborations with hospitals and clinical researchers, further validating cold plasma’s efficacy for complex chronic wounds and infection control.

Adtec Healthcare’s technology addresses one of the most pressing challenges in modern medicine: antibiotic resistance. The SteriPlas device uses cold atmospheric plasma to deactivate bacteria and biofilms without damaging surrounding tissue. Clinical trials have demonstrated that the therapy can speed up wound healing, reduce infection recurrence, and improve patient outcomes—all without antibiotics.

While the medtech market remains highly competitive, Adtec Healthcare benefits from a proven product and two decades of scientific development inherited from its Japanese parent company. Its challenge now lies in scaling production, securing U.S. regulatory approval, and establishing reimbursement pathways in key healthcare markets. Success in these areas could position the company as a leader in the global wound-care and infection-control market, valued in the billions annually.

The funding from AIPO Fund and SG Biomedical provides the financial runway needed for this next stage of growth. Both investors are aligned with Adtec Healthcare’s vision to deliver safer, faster, and more effective alternatives to traditional wound-care methods. With the U.S. market in its sights and demand for non-antibiotic therapies increasing worldwide, Adtec Healthcare is well-positioned to make cold plasma a transformative force in medical treatment.

Adtec Healthcare’s $12 million funding round underscores growing confidence in innovative, antibiotic-free medical technologies. With backing from AIPO Fund and SG Biomedical, the company now enters a critical scale-up phase—one that could see its plasma-based wound-care devices adopted across major healthcare systems globally.